Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardent Health, Inc. filings document the formal reporting record for a public healthcare provider operating acute care hospitals and related sites of care through subsidiaries. Form 8-K disclosures furnish quarterly operating results, including revenue, admissions measures, net patient service revenue, adjusted EBITDA, and related non-GAAP reconciliations.
The filing record also covers governance and capital-structure matters. Proxy materials describe annual-meeting proposals, director elections, executive compensation, equity awards, and pay-versus-performance data. Other 8-K filings report executive-separation and severance arrangements, a common stock repurchase authorization, and amendments to term loan and asset-based lending credit agreements involving subsidiary borrowers and guarantors.
Ardent Health, Inc. reported first quarter 2026 results showing solid top-line and profit growth. Total revenue rose 7.0% year-over-year to $1.60 billion, driven by a 2.0% increase in adjusted admissions and a 5.5% increase in net patient service revenue per adjusted admission.
Net income attributable to Ardent Health was $39.9 million, or $0.28 per diluted share, compared with $41.4 million, or $0.29, a year earlier as margin mix and non-operating items shifted. Adjusted EBITDA increased 26.3% to $124 million, and excluding a $10.9 million investment gain, grew 15%.
Operationally, total surgeries grew 1.2% while admissions declined 1.1%, reflecting severe weather and a lighter respiratory season. As of March 31, 2026, Ardent held $610 million of cash, $1.1 billion of total debt, and a lease-adjusted net leverage ratio of 2.6x, improved from 3.0x a year earlier. The company reaffirmed full-year 2026 guidance, including total revenue of $6.4–$6.7 billion and Adjusted EBITDA of $485–$535 million.
Ardent Health, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on May 20, 2026. Holders of 143,095,662 outstanding common shares as of March 26, 2026 may vote.
Stockholders will elect 11 directors, approve on a non-binding basis executive pay, and ratify Ernst & Young LLP as auditor for 2026. Ardent is a controlled company, with EGI‑AM owning about 54% of the voting power and Pure Health about 21.1%. The proxy describes committee structures, director independence determinations, and a compensation program focused on base salary, annual cash incentives, and performance-based equity. For 2025, revenue was $6.3 billion with 6% growth, adjusted EBITDA rose 9%, and operating cash flow reached $471 million, supporting pay decisions and performance-based awards.
Ardent Health, Inc. director Peter J. Bulgarelli reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units at no cash exercise price. Following this award, he holds 14,231 shares directly. The units vest in full on the first anniversary of April 1, 2026, conditioned on his continued service with the company through that vesting date.
Havdala Ellen reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Ellen Havdala reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units will vest in full on the first anniversary of April 1, 2026, as long as she continues serving the company through that date. After this grant, she holds 115,367 shares of common stock directly.
Sotir Mark R reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director and Chair of the Board Mark R. Sotir received an award of 14,231 shares of Common Stock in the form of restricted stock units at no purchase price. These units vest in full on the first anniversary of April 1, 2026, contingent on his continued service with the company. Following this grant, he holds 38,709 shares directly.
Sen Rahul reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Rahul Sen reported an award of 14,231 shares of Common Stock in the form of restricted stock units. These units were granted at no cash cost and will vest in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this compensation-related grant, Sen’s directly owned and awarded position totals 38,709 shares.
Webb Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Robert Thomas Webb reported an equity award of 14,231 shares of Common Stock, received as a grant on April 1, 2026 at no purchase price. These represent restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, Webb directly holds a total of 78,215 shares of Common Stock.
Robinson Edmondo reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Edmondo Robinson received a grant of 14,231 shares of Common Stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company through that date. Following this award, he directly holds 58,215 shares of Common Stock.